MDGL - シンタ・ファ―マシュ―ティカルズ （Madrigal Pharmaceuticals Inc.） シンタ・ファ―マシュ―ティカルズMDGLのチャート
MDGLの企業情報
| symbol | MDGL |
|---|---|
| 会社名 | Madrigal Pharmaceuticals Inc （シンタ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 マドリガル・ファーマシューティカルズ（Madrigal Pharmaceuticals Inc）(旧名：Synta Pharmaceuticals Corp.)は臨床病期のバイオ医薬品会社である。同社は心血管代謝疾患および非アルコール性脂肪性肝炎（NASH）の治療用の治療候補の開発・商業化に従事する。主力製品であるMGL-3196は、NASHの治療用第Ⅱ相準備の1日1回、経口、肝臓特異的選択甲状腺ホルモン受容体-b（THR-b）アゴニスト、および異型接合性および同型接合性家族性高コレステロール血症（FH）である。その製品パイプラインには、NASHとFHの治療に使用されるMGL-3745も含まれる。MGL-3196は、健康なボランティアで第I相単回投与および複数回投与試験を完了し、低密度リポタンパク質コレステロール、トリグリセリドレベルおよびリポタンパク質（a）を低下させるための異常脂質血症/高コレステロール血症のために開発されている。また、脂肪代謝を増加させることによって血漿・肝臓中のトリグリセリドを減少させ、抗糖尿病作用を示す。 シンタ・ファ―マシュ―ティカルズは米国のバイオ医薬品メ―カ―。主にがんや慢性炎症性疾患などの、重篤な病状や患者のための小分子薬の発見・開発・製品化に取り組む。臨床段階のがんの候補薬や、前臨床段階の炎症性疾患治療薬の開発プログラムを保有する。本社はマサチュ―セッツ州レキシントン。 Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal recognizes that compounds with greater selectivity for thyroid hormone receptor (THR)-ß and liver uptake has the greatest potential to overcome challenges faced by prior, less selective compounds and deliver the full therapeutic potential of THR-ß agonism. The Company believes that resmetirom, its lead product candidate, is the first orally administered, small-molecule, liver-directed, truly ß-selective THR agonist. |
| 本社所在地 | Four Tower Bridge 200 Barr Harbor Drive Suite 400 West Conshohocken PA 19428 USA |
| 代表者氏名 | Paul A. Friedman ポール・A・フリードマン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 404-380-9263 |
| 設立年月日 | 36586 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 8人 |
| url | www.syntapharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mdgl |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -32.32700 |
| 終値（lastsale） | 199.3138 |
| 時価総額（marketcap） | 3062782215.7492 |
| 時価総額 | 時価総額（百万ドル） 2957.77 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2467.465 |
| 当期純利益 | 当期純利益（百万ドル） -29.63200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Madrigal Pharmaceuticals Inc revenues was not reported. Net loss decreased 11% to $12.8M. Lower net loss reflects Interest income increase from $168K to $1.9M (income) Research and development decrease of 16% to $9.2M (expense) General and administrative decrease of 2% to $2.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.20 to -$0.90. |
MDGLのテクニカル分析
MDGLのニュース
Madrigal Pharmaceuticals PT Raised to $182 at JMP Securities 2022/09/02 06:59:04 Investing.com
https://www.investing.com/news/pro/madrigal-pharmaceuticals-pt-raised-to-182-at-jmp-securities-432SI-2884845
Viking Therapeutics: Playing Second Fiddle To Madrigal (NASDAQ:VKTX) 2022/08/30 10:14:12 Seeking Alpha
Viking Therapeutics (VKTX) has a compound similar to Madrigal Pharmaceuticals'', only a few years later in development. Read more here.
Madrigal Pharmaceuticals GAAP EPS of -$4.14 misses by $0.46 2022/08/04 12:30:59 Seeking Alpha
Madrigal Pharmaceuticals press release (MDGL): Q2 GAAP EPS of -$4.14 misses by $0.46.As of June 30, 2022, Madrigal had cash, cash equivalents and marketable securities of $211.8…
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results 2022/08/04 12:00:00 GlobeNewswire
CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports its second quarter 2022 financial results.
MDGL stock lower as B. Riley downgrades on concerns over upcoming NASH data (NASDAQ:MDGL) 2022/07/08 15:39:57 Seeking Alpha
B Riley Securities has downgraded the clinical-stage biotech Madrigal Pharmaceuticals (MDGL) to Neutral from Buy, questioning the potential of a late-stage study for the company’s…
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences 2022/05/17 12:00:00 GlobeNewswire
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming investor conferences:
Madrigal Pharmaceuticals, Inc. (MDGL) CEO Paul Friedman on Q1 2022 Results - Earnings Call Transcript 2022/05/09 16:56:06 Seeking Alpha
Madrigal Pharmaceuticals, Inc. (NASDAQ:NASDAQ:MDGL) Q1 2022 Results Earnings Conference Call May 09, 2022, 08:00 AM ET Company Participants Paul Friedman - Chairman and Chief Executive…
Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch 2022/05/09 14:14:09 Benzinga
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) secured a $250 million term loan facility from Hercules Capital Inc (NYSE: HTGC ), providing additional funding to support the expanded clinical program and ramp-up for a potential US launch of resmetirom. The company drew $50 million from the facility at closing and can draw a … Full story available on Benzinga.com
Recap: Madrigal Pharmaceuticals Q1 Earnings 2022/05/09 10:40:37 Benzinga
Madrigal Pharmaceuticals (NASDAQ: MDGL ) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Madrigal Pharmaceuticals beat estimated earnings by 7.18%, reporting … Full story available on Benzinga.com
Madrigal Pharmaceuticals GAAP EPS of -$3.36 beats by $0.20 2022/05/09 10:32:22 Seeking Alpha
Madrigal Pharmaceuticals press release (MDGL): Q1 GAAP EPS of -$3.36 beats by $0.20.As of March 31, 2022, Madrigal had cash, cash equivalents and marketable securities of $220.0…
The Behavior Of Madrigal Pharmaceuticals Inc. (MDGL) Stock Is Not As Predictable As You Think 2022/03/19 18:00:00 Stocks Register
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) concluded the trading at $98.71 on Friday, March 18 with a rise of 0.58% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $98.14 and 5Y monthly beta was reading 1.15 with its price kept floating in the … The Behavior Of Madrigal Pharmaceuticals Inc. (MDGL) Stock Is Not As Predictable As You Think Read More »
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference 2022/03/09 21:30:00 GlobeNewswire
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.
Madrigal Pharmaceuticals Q4 net loss widens Y/Y 2022/02/24 14:48:53 Seeking Alpha
Madrigal Pharmaceuticals (MDGL) Q4 net loss increased to -$64.55M, compared to -$59.12M in Q4 2020. Q4 net interest income was $52K, compared to $432K in the prior year period. The…
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results 2022/02/24 13:00:00 GlobeNewswire
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results.
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Fell -3.22%, Now What? Dont Panic 2022/02/12 13:30:00 Stocks Register
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) price on Friday, February 11, fall -3.22% below its previous days close as a downside momentum from buyers pushed the stocks value to $87.37. A look at the stocks price movement, the close in the last trading session was $90.28, moving within a range at $86.60 and $92.45. The beta value Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Fell -3.22%, Now What? Dont Panic Read More »